A One-Step Electrochemical Aptasensor Based on Signal Amplification of Metallo Nanoenzyme Particles for Vascular Endothelial Growth Factor

Mei, Chenyang; Zhang, Yuanyuan; Pan, Luting; Dong, Bin; Chen, Xingwei; Gao, Qingyi; Xu, Hang; Xu, Wenjin; Fang, Hui; Liu, Siyu; McAlinden, Colm; Paschalis, Eleftherios I.; Wang, Qinmei; Yang, Mei; Huang, Jinhai; Yu, A-Yong

doi:10.3389/fbioe.2022.850412

Cited by 7 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 84 An anti-VEGF aptamer has also been used to establish a target-induced dissociation assay using thermophoresis and microarrays, which can detect 0.1 nM of VEGF, 49 , 85 and another has been used to develop an electrochemical aptasensor based on metallo nanoenzyme particles to amplify the VEGF signal to facilitate its detection. 86 Gao et al constructed a biolayer interferometry-based enzyme-linked aptamer sorbent assay based on anti-PDGF-BB, allowing rapid, high-throughput processing and real-time monitoring. 87 The generation of these detection methods indicates the new direction of aptamer application in AMD and the importance of biomarker detection for early diagnosis and therapy of the disease.…”

Section: Aptamers Applied In Ophthalmology Researchmentioning

confidence: 99%

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Cao¹,

Zhang²,

Xiong³

2023

IJN

View full text Add to dashboard Cite

Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.

show abstract

Section: Aptamers Applied In Ophthalmology Researchmentioning

confidence: 99%

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Cao¹,

Zhang²,

Xiong³

2023

IJN

View full text Add to dashboard Cite

show abstract

“…The repeatability, specificity, and reliability of this aptasensor are superior to that of the traditional immunoturbidimetry assay, suggesting that it has great prospects in clinical diagnostic applications of cardiovascular disease. Vascular endothelial growth factor (VEGF) is a key biomarker of diabetic retinopathy (DR), which can be also determined by electrochemical aptasensors [95]. For instance, Mei et al designed a noninvasive electrochemical aptasensor to detect VEGF in tears [96].…”

Section: Detection Of Proteinsmentioning

confidence: 99%

Recent Progress in Electrochemical Aptasensors: Construction and Application

Yuan,

Cai,

et al. 2023

Chemosensors

View full text Add to dashboard Cite

Electrochemical aptasensors have gained significant attention due to their exceptional sensitivity, selectivity, stability, and rapid response, combining the advantages of electrochemical techniques with the specific recognition ability of aptamers. This review aims to provide a comprehensive summary of the recent advances in electrochemical aptasensors. Firstly, the construction method and the advantages of electrochemical aptasensors are introduced. Subsequently, the review highlights the application progress of electrochemical aptasensors in detecting various chemical and biological molecules, including metal ions, small biological molecules, drugs, proteins, exosomes, tumor cells, bacteria, and viruses. Lastly, the prospects and challenges associated with electrochemical aptasensors are discussed.

show abstract

“…Electrochemical impedance spectroscopy (EIS) measures the electrochemical performance of the aptasensor. High specificity and repeatability were also demonstrated by the electrochemical aptasensor [ 105 ].…”

Section: Aptamer Mediated Targeting Of Vegfmentioning

confidence: 99%

“…One of the most crucial difficulties with anti-VEGF aptamers is biocompatibility. The standard technology of aptamers is advancing while their production cost remains expensive compared with traditional antibodies [ 105 ].…”

Section: Aptamers Targeting Vegf In the Ovarian Cancer Therapymentioning

confidence: 99%

Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer

Mishra,

Chattaraj,

Mishra

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Cancer is one of the diseases that causes a high mortality as it involves unregulated and abnormal cell growth proliferation that can manifest in any body region. One of the typical ovarian cancer symptoms is damage to the female reproductive system. The death rate can be reduced through early detection of the ovarian cancer. Promising probes that can detect ovarian cancer are suitable aptamers. Aptamers, i.e., so-called chemical antibodies, have a strong affinity for the target biomarker and can typically be identified starting from a random library of oligonucleotides. Compared with other probes, ovarian cancer targeting using aptamers has demonstrated superior detection effectiveness. Various aptamers have been selected to detect the ovarian tumor biomarker, vascular endothelial growth factor (VEGF). The present review highlights the development of particular aptamers that target VEGF and detect ovarian cancer at its earliest stages. The therapeutic efficacy of aptamers in ovarian cancer treatment is also discussed.

show abstract

A One-Step Electrochemical Aptasensor Based on Signal Amplification of Metallo Nanoenzyme Particles for Vascular Endothelial Growth Factor

Cited by 7 publications

References 37 publications

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

Recent Progress in Electrochemical Aptasensors: Construction and Application

Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer

Contact Info

Product

Resources

About